RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Abionyx Pharma Revenue 2024

Abionyx Pharma Revenue

4.69 M EUR

Abionyx Pharma Dividend yield

Ticker

ABNX.PA

ISIN

FR0012616852

WKN

A14QR9

In 2024, Abionyx Pharma's sales reached 4.69 M EUR, a 1.12% difference from the 4.64 M EUR sales recorded in the previous year.

The Abionyx Pharma Revenue history

YEARREVENUE (undefined EUR)GROSS MARGIN (%)
2026e14.184,36
2025e7.248,53
2024e4.6913,17
20234.6413,32
20225.2512,11
20210.6838,37
2020--
2019--
20180.17355,17
2017--
2016--
2015--
2014--
2013--

Abionyx Pharma Aktienanalyse

What does Abionyx Pharma do?

Abionyx Pharma SA is a biotechnology company based in France that specializes in the development and commercialization of innovative therapeutic approaches for rare diseases. The company was founded in 2000 by a group of scientists and pharmaceutical experts and has since become a leading company in the industry. The business model of Abionyx Pharma is based on the discovery and development of drugs for rare diseases. The company focuses in particular on diseases for which there are still no or only inadequate therapies. With this focus, Abionyx Pharma takes advantage of orphan drug designations and other incentive programs offered by governments and authorities around the world. These programs are intended to provide incentives for the research and development of drugs for rare diseases. Abionyx Pharma has a wide range of products in various stages of development. These include therapeutics for musculoskeletal diseases, neural disorders, and chronic inflammation. The company also has a portfolio of compounds and drugs that can be used as a platform for the development of drugs for other diseases. One of Abionyx Pharma's key products is ONO-8455, a treatment package for osteoarthritis. This is a common joint disease caused by progressive cartilage wear. ONO-8455 has the potential to be a very important therapy option for the disease and could potentially become a blockbuster drug. Another important product from Abionyx Pharma is ABX464. This is a topical therapy for the treatment of hemorrhoid inflammation. ABX464 has been tested in clinical trials and has shown promising results in terms of its effectiveness in treating hemorrhoids. Abionyx Pharma also has other projects in the pipeline, including a therapy for Fabry disease. Fabry disease is a very rare genetic disorder that affects the metabolism of lipids and other important molecules in the body. Abionyx Pharma is developing a therapy based on a novel technology that acts through DNA methylation. To achieve its business goals, Abionyx Pharma works closely with scientific and clinical partners. It also forms strategic alliances with other pharmaceutical companies to market its products globally and gain a significant market share. Overall, Abionyx Pharma is an attractive company for investors looking for a biotechnology company specializing in the development and commercialization of drugs for rare diseases. The company has a strong portfolio of products in various stages of development and has already presented promising results. With its close collaboration with partners and strategic alliances, it is able to market its products globally and remain a strong competitor in the industry. Abionyx Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Abionyx Pharma's Sales Figures

The sales figures of Abionyx Pharma originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Abionyx Pharma’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Abionyx Pharma's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Abionyx Pharma’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Abionyx Pharma Stock

How much revenue did Abionyx Pharma generate this year?

Abionyx Pharma has achieved a revenue of 4.69 M EUR this year.

How much was the turnover of the company Abionyx Pharma compared to the previous year?

The revenue of Abionyx Pharma has increased by 1.12% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Abionyx Pharma?

The revenue of Abionyx Pharma is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Abionyx Pharma measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Abionyx Pharma so important for investors?

The revenue of Abionyx Pharma is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Abionyx Pharma pay?

Over the past 12 months, Abionyx Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Abionyx Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Abionyx Pharma?

The current dividend yield of Abionyx Pharma is .

When does Abionyx Pharma pay dividends?

Abionyx Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Abionyx Pharma?

Abionyx Pharma paid dividends every year for the past 0 years.

What is the dividend of Abionyx Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Abionyx Pharma located?

Abionyx Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Abionyx Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Abionyx Pharma from 5/20/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/20/2024.

When did Abionyx Pharma pay the last dividend?

The last dividend was paid out on 5/20/2024.

What was the dividend of Abionyx Pharma in the year 2023?

In the year 2023, Abionyx Pharma distributed 0 EUR as dividends.

In which currency does Abionyx Pharma pay out the dividend?

The dividends of Abionyx Pharma are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Abionyx Pharma

Our stock analysis for Abionyx Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Abionyx Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.